07:56 AM EDT, 08/27/2024 (MT Newswires) -- Avicanna Inc. ( AVCNF ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced Tuesday the United States Patent and Trademark Office issuance of the Patent covering Avicanna's ( AVCNF ) deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.

"We are very happy with the issuance of another USPTO patent, this time on transdermal topical technology that has been a significant part of our research & development, R&D and clinical efforts. This technology was created through years of development, including AI guided prediction modelling, pre-clinical trials and real-world evidence and is part of our RHO Phyto commercial portfolio. We look forward to the incorporation of our patented technologies as we move forward to further evolving our pipeline, particularly those that target musculoskeletal pain and inflammation," said Aras Azadian, CEO, in a statement.